Korea S.E.
18:00:00 2024-05-16 EDT
5-day change
1st Jan Change
65,700
KRW
+0.61%
+0.77%
-4.92%
Dong-A ST Co., Ltd. authorizes a Buyback Plan.
The Board of Directors of Dong-A ST Co., Ltd. has authorized a buyback plan on October 26, 2022.
Idience Co., Ltd announced that it expects to receive KRW 25.00000052 billion in funding from Dong-A ST Co., Ltd.
2024-05-19
CI
Dong-A ST Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-18
CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd.
01-23
CI
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara
01-05
CI
Dong-A ST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
MEZOO Co.,Ltd. announced that it has received KRW 18 billion in funding from a group of investors
11-06
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023.
23-10-19
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on July 26, 2023.
23-10-19
CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on July 26, 2023, has closed with 38,373 shares, representing 0.45% for KRW 2,296.31 million.
23-10-16
CI
Dong-A ST Sets Sight on European Market with Stelara Biosimilar Expansion
23-08-31
MT
Dong-A ST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 38,373 shares.
23-07-26
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023.
23-07-25
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on April 26, 2023.
23-07-25
CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan.
23-07-25
CI
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
23-07-17
CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on April 26, 2023, has closed with 45,872 shares, representing 0.54% for KRW 2,520.87 million.
23-07-16
CI
Dong-A ST Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 45,872 shares.
23-04-26
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.
23-04-26
CI
Tranche Update on Dong-A ST Co., Ltd.'s Equity Buyback Plan announced on January 26, 2023.
23-04-26
CI
Dong-A ST Co., Ltd. authorizes a Buyback Plan.
23-04-25
CI
Dong-A ST Co., Ltd.'s Equity Buyback announced on January 26, 2023, has closed with 40,519 shares, representing 0.47% for KRW 2,405.93 million
23-04-24
CI
GenEdit Inc. amended terms of the transaction
23-02-27
CI
Dong-A ST Co., Ltd. announces an Equity Buyback for 40,519 shares.
23-01-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
More about the company
1st Jan change
Capi.
-4.92% 422M +10.49% 8.96B -10.76% 5.19B +51.58% 4.77B +12.50% 4.26B -20.70% 2.37B +13.08% 2.3B -29.65% 2.21B +19.51% 2.17B -0.50% 1.64B
Specialty & Advanced Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DONG-A ST CO., LTD. 
